erlotinib hydrochloride has been researched along with pyrimidinones in 7 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pyrimidinones) | Trials (pyrimidinones) | Recent Studies (post-2010) (pyrimidinones) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,059 | 604 | 2,692 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bernards, R; Cowell, C; de Bruin, EC; Downward, J; García-Castaño, A; Gettinger, S; Gómez-Román, J; Gong, Y; Heideman, DA; Heynen, GJ; Jiang, M; Ladanyi, M; Melnick, MA; Politi, K; Saunders, RE; Smit, EF; Varmus, H; Walther, Z; Warne, PH; Wurtz, A | 1 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ | 1 |
| Black, EP; Overley, CW; Ratermann, KL; Stamatkin, C | 1 |
| Azan, A; Bakker Schut, TC; Besse, B; Boutros, C; Caspers, PJ; Eggermont, AM; Kamsu Kom, N; Koljenović, S; Lanoy, E; Mateus, C; Mir, LM; Noordhoek Hegt, V; Paci, A; Planchard, D; Puppels, GJ; Robert, C; Routier, E; Roy, S; Seck, A; Texier, M; Tomasic, G | 1 |
| Li, Y; Owonikoko, TK; Qian, G; Ramalingam, SR; Sun, SY; Zang, H | 1 |
| Ahn, L; Arcila, ME; Hayes, SA; Iqbal, A; Kris, MG; Luo, J; Makhnin, A; Ng, K; Riely, GJ; Tobi, Y; Yu, HA | 1 |
1 trial(s) available for erlotinib hydrochloride and pyrimidinones
| Article | Year |
|---|---|
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
Topics: Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Biomarkers; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Male; Middle Aged; Oximes; Pilot Projects; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; ROC Curve; Sensitivity and Specificity; Skin; Spectrum Analysis, Raman; Sulfonamides; Vemurafenib | 2017 |
6 other study(ies) available for erlotinib hydrochloride and pyrimidinones
| Article | Year |
|---|---|
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Neoplasms, Experimental; Neurofibromin 1; Pyridones; Pyrimidinones | 2014 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib | 2015 |
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression; Humans; Inhibitory Concentration 50; Isoenzymes; Lung Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Purines; Pyrimidinones; Quinazolinones; Triazines | 2015 |
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2020 |
Erlotinib and Trametinib in Patients With
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones | 2021 |